Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.

List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E.

J Clin Oncol. 2012 Jun 10;30(17):2134-9. doi: 10.1200/JCO.2010.34.1222. Epub 2012 Apr 30.

PMID:
22547607
2.

Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.

Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.

Transfusion. 2015 Jul;55(7):1613-20. doi: 10.1111/trf.13036. Epub 2015 Mar 11.

PMID:
25764017
3.

Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.

Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10.

PMID:
24580147
4.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
5.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C.

Leuk Res. 2010 Dec;34(12):1560-5. doi: 10.1016/j.leukres.2010.06.013. Epub 2010 Jul 8.

PMID:
20615548
6.

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.

Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.

Free Radic Biol Med. 2012 Aug 15;53(4):643-8. doi: 10.1016/j.freeradbiomed.2012.06.006. Epub 2012 Jun 15.

PMID:
22705364
7.

Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.

Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.

Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17.

PMID:
28419408
8.

Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.

Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.

Eur J Haematol. 2015 Jul;95(1):52-6. doi: 10.1111/ejh.12476. Epub 2015 Mar 12.

PMID:
25764148
9.

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study.

Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C.

Eur J Haematol. 2008 Feb;80(2):168-76. Epub 2007 Nov 17.

10.

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.

Gattermann N, Jarisch A, Schlag R, Blumenstengel K, Goebeler M, Groschek M, Losem C, Procaccianti M, Junkes A, Leismann O, Germing U.

Eur J Haematol. 2012 Mar;88(3):260-8. doi: 10.1111/j.1600-0609.2011.01726.x. Epub 2011 Nov 24.

11.

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias.

Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators.

Eur J Haematol. 2011 Oct;87(4):338-48. doi: 10.1111/j.1600-0609.2011.01660.x. Epub 2011 Jul 29.

12.

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.

Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators.

Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30.

13.

Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.

Metzgeroth G, Dinter D, Schultheis B, Dorn-Beineke A, Lutz K, Leismann O, Hehlmann R, Hastka J.

Ann Hematol. 2009 Apr;88(4):301-10. doi: 10.1007/s00277-008-0588-3. Epub 2008 Aug 29.

PMID:
18758781
14.

Efficacy and safety of deferasirox in myelodysplastic syndromes.

Breccia M, Alimena G.

Ann Hematol. 2013 Jul;92(7):863-70. doi: 10.1007/s00277-013-1703-7. Epub 2013 Feb 17. Review.

PMID:
23417759
15.

[Efficacy and safety of deferasirox in aplastic anemia patients with iron overload: a single arm, multi-center,prospective study in China].

Shi J, Chang H, Zhang L, Shao Y, Nie N, Zhang J, Huang J, Zhang L, Tang X, Quan R, Zheng C, Xiao H, Hu D, Hu L, Liu F, Zhou Y, Zheng Y, Zhang F.

Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):1-6. doi: 10.3760/cma.j.issn.0253-2727.2016.01.001. Chinese.

PMID:
26876245
16.

A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis.

Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, Malfertheiner P, McLaren GD, Niederau C, Piperno A, Powell LW, Russo MW, Stoelzel U, Stremmel W, Griffel L, Lynch N, Zhang Y, Pietrangelo A.

Hepatology. 2010 Nov;52(5):1671-779. doi: 10.1002/hep.23879.

17.

Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.

Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.

Ann Hematol. 2010 Feb;89(2):147-54. doi: 10.1007/s00277-009-0794-7. Epub 2009 Aug 19.

PMID:
19690857
18.

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.

Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators.

Leuk Res. 2010 Sep;34(9):1143-50. doi: 10.1016/j.leukres.2010.03.009. Epub 2010 May 6.

PMID:
20451251
19.

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, Petrucci L, Salaroli A, Serrao A, Latagliata R, Alimena G.

Ann Hematol. 2012 Sep;91(9):1345-9. doi: 10.1007/s00277-012-1481-7. Epub 2012 May 9.

PMID:
22569854
20.

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Porter JB, Elalfy MS, Taher AT, Aydinok Y, Chan LL, Lee SH, Sutcharitchan P, Habr D, Martin N, El-Beshlawy A.

Ann Hematol. 2013 Jan;92(2):211-9. doi: 10.1007/s00277-012-1588-x. Epub 2012 Oct 21.

Supplemental Content

Support Center